These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 92567)

  • 1. Ribose and Deoxyribose Group Alter Excited-State Dynamics of 5-Azacytosine in Solution.
    Chen Z; Wang X; Jia M; He X; Pan H; Chen J
    Photochem Photobiol; 2024; 100(2):291-297. PubMed ID: 35993879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoic acid-inducible gene-I like receptor pathway in cancer: modification and treatment.
    Du G; Xing Z; Zhou J; Cui C; Liu C; Liu Y; Li Z
    Front Immunol; 2023; 14():1227041. PubMed ID: 37662910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in DNA methyltransferase inhibitors as anticancer agents.
    Zhang Z; Wang G; Li Y; Lei D; Xiang J; Ouyang L; Wang Y; Yang J
    Front Pharmacol; 2022; 13():1072651. PubMed ID: 37077808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.
    Ribeiro ML; Reyes-Garau D; Armengol M; Fernández-Serrano M; Roué G
    Front Genet; 2019; 10():986. PubMed ID: 31681423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate.
    Heideman RL; McCully C; Balis FM; Poplack DG
    Invest New Drugs; 1993; 11(2-3):135-40. PubMed ID: 7505267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.
    Wallace RE; Lindh D; Durr FE
    Cancer Chemother Pharmacol; 1989; 25(2):117-23. PubMed ID: 2480854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.
    Avramis VI; Powell WC; Mecum RA
    Cancer Chemother Pharmacol; 1989; 25(1):19-24. PubMed ID: 2480187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a 72-h continuous-infusion schedule of fazarabine.
    Amato R; Ho D; Schmidt S; Krakoff IH; Raber M
    Cancer Chemother Pharmacol; 1992; 30(4):321-4. PubMed ID: 1379523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
    Yang GS; McCulloch EA
    Hematol Pathol; 1992; 6(3):125-30. PubMed ID: 1385380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.
    Grem JL; Shoemaker DD; Hoth DF; King SA; Plowman J; Zaharko D; Grieshaber CK; Harrison SD; Cradock JC; Leyland-Jones B
    Invest New Drugs; 1987 Dec; 5(4):315-28. PubMed ID: 2449402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid nucleoside conjugates for the treatment of cancer.
    Alexander RL; Kucera GL
    Curr Pharm Des; 2005; 11(9):1079-89. PubMed ID: 15853657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antitumor activity of 5-azacytosine arabinoside.
    Beisler JA; Abbasi MM; Driscoll JS
    J Med Chem; 1979 Oct; 22(10):1230-4. PubMed ID: 92567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.
    Driscoll JS; Johns DG; Plowman J
    Invest New Drugs; 1985; 3(4):331-4. PubMed ID: 2417984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.